CORANGE BATTLE WITH ENGELHORN

10 April 1994

Corange, the Bermuda-based parent company of the German pharmaceutical group Boehringer Mannheim, is facing the threat of its biggest single shareholder, Curt Engelhorn, selling his stake in the company (Marketletter March 21).

Mr Engelhorn controls 42% of Corange shares through three different trusts as chairman of the supervisory body of Boehringer Mannheim. He says that he is not prepared to hold shares in a company in which he has no say, according to a report in the Financial Times. The Corange board is attempting to eject Mr Engelhorn.

He was chief executive of the group for 30 years until 1990. He is reported to have sent a letter to members of his family demanding the resignation of Max Link, Corange's current chief executive.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight